TITLE:
Astragaloside IV Ameliorates Inflammatory Damage in Mice with Acute Liver Failure
AUTHORS:
Ying Yang, Meng Hong, Wenwen Lian, Zhi Chen
KEYWORDS:
Astragaloside IV, Acute Liver Failure, Inflammation, Monocyte, Autophagy
JOURNAL NAME:
Chinese Medicine,
Vol.14 No.4,
October
19,
2023
ABSTRACT: Acute liver failure is a life-threatening clinical
syndrome with a high mortality rate. Currently, the research on Astragaloside
IV in liver diseases primarily focuses on liver cancer, and there is limited
understanding of its mechanism in acute liver failure’s innate immunity.
Therefore, this study aims to investigate
the potential protective effect of Astragaloside IV on acute liver failure and its impact on innate immune cells. The study employed D-GalN/LPS-induced acute
liver failure mouse models and employed various techniques such as a range of
molecular and analytical techniques. The experimental results demonstrated that
treatment with Astragaloside IV significantly reduced the inflammatory
response, alleviated liver injury, and improved the survival rate of mice with
acute liver failure induced by D-GalN/LPS. Further investigations revealed that
AS-IV played a beneficial role by regulating the proportion of CD11b+Ly6Chi monocytes and the secretion of inflammatory cytokines and anti-inflammatory
metabolites. These findings suggest that the pharmacological mechanism of AS-IV
may involve targeted regulation of CD11b+Ly6Chi monocytes
in both peripheral blood and liver. The implications of this study’s results
are twofold. Firstly, they provide a basis for the clinical application of
AS-IV in treating liver failure, offering potential therapeutic benefits.
Secondly, they serve as a reference for further development of safer and more
effective modified compounds.